PURPOSE: To assess the activity and toxicity of gemcitabine in locally advanced or metastatic soft tissue sarcoma patients (pts). PATIENTS AND METHODS: Gemcitabine was administered on days 1, 8, 15 every 4 weeks at a dose of 1.000/1.250 mg/m2, respectively, in pretreated or not pretreated pts. RESULTS:Eighteen pts entered this phase II trial; sixteen had been previously treated withanthracyclines and ifosfamide. A partial response was observed in a woman with fibrous malignant istocytoma, whereas in 7 pts the disease remained stable. Median time to progression was 4 months. The treatment was well tolerated. Grade 4 toxicity was not observed. CONCLUSIONS: These results do not suggest that gemcitabine, in the dose and schedule used in this trial, may be of value in the treatment of soft tissue sarcomas.
RCT Entities:
PURPOSE: To assess the activity and toxicity of gemcitabine in locally advanced or metastatic soft tissue sarcomapatients (pts). PATIENTS AND METHODS: Gemcitabine was administered on days 1, 8, 15 every 4 weeks at a dose of 1.000/1.250 mg/m2, respectively, in pretreated or not pretreated pts. RESULTS: Eighteen pts entered this phase II trial; sixteen had been previously treated with anthracyclines and ifosfamide. A partial response was observed in a woman with fibrous malignant istocytoma, whereas in 7 pts the disease remained stable. Median time to progression was 4 months. The treatment was well tolerated. Grade 4 toxicity was not observed. CONCLUSIONS: These results do not suggest that gemcitabine, in the dose and schedule used in this trial, may be of value in the treatment of soft tissue sarcomas.
Authors: A López-Pousa; R Losa; J Martín; J Maurel; J Fra; M Sierra; A Casado; J García Del Muro; A Poveda; C Balañá; J Martínez-Trufero; E Esteban; J M Buesa Journal: Br J Cancer Date: 2006-05-23 Impact factor: 7.640
Authors: Joshua D Schoenfeld; Zita A Sibenaller; Kranti A Mapuskar; Megan D Bradley; Brett A Wagner; Garry R Buettner; Varun Monga; Mohammed Milhem; Douglas R Spitz; Bryan G Allen Journal: Redox Biol Date: 2017-09-28 Impact factor: 11.799